 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE has announced that the US Patent and Trademark Office has issued Patent No. 11,458,109, titled Treatment of 22q11.2 Deletion Syndrome With Cannabidiol, which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol. 